Skip to content

Integra LifeSciences to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference and Canaccord Genuity Global Healthcare Conference


<< Back

Press Release

Jul 30, 2010

Integra LifeSciences to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference and Canaccord Genuity Global Healthcare Conference

PLAINSBORO, N.J., July 30, 2010 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will present at two conferences in August.

On Thursday, August 5th, 2010 at 8:30 am ET, Mr. Gerry Carlozzi, Executive Vice President and Chief Operating Officer of Integra, will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference at the Sheraton New York Hotel in New York City. A live webcast of the presentation will be available via a link on the Investor Relations page of our website at www.integralife.com.

On Tuesday, August 10th, 2010 at 1:30 pm ET, Mr. Stuart Essig, President and CEO of Integra, will present at the Canaccord Genuity Global Healthcare Conference at the Intercontinental Hotel in Boston, MA. There will be no webcast for this presentation.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Our products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information, visit www.integralife.com.

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

IART-G

CONTACT:  Integra LifeSciences Holdings Corporation
          John B. Henneman, III, Executive Vice President, 
           Finance and Administration and Chief Financial Officer
            (609) 275-0500
            jack.henneman@integralife.com
          Investor Relations:
          Angela Steinway
            (609) 936-2268
            angela.steinway@integralife.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.